During the 4th European CAR T-Cell Meeting, the Lymphoma Hub was pleased to speak with Daniel Chen, University College Hospitals, London, UK. We asked, How common are cardiotoxic events in patients receiving CD19 CAR T cells? What are the risk factors?

Chen begins by highlighting the increased recognition of cardiovascular complications and toxicity in CAR T-cell treatment and their manifestations. He discusses some retrospective analyses that tried to identify patients most at risk of developing these complications. Finally he outlines the risk factors for cardiovascular toxicities such as high disease burden and cytokine release syndrome.

свернуть